Company ProfilePremium

Disc Medicine Inc

Company Profile Analysis

Ticker: IRON

ESOMAR 23 Corporate BadgeISO Certifications Badge
Disc Medicine Inc - Company showcase

Year Founded & Workforce

2022

165 Employees

Disc Medicine Inc logo

Disc Medicine Inc Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Disc Medicine Inc Overview

Disc Medicine is a Watertown, Massachusetts–based clinical-stage biopharmaceutical company built around a single, unusually coherent scientific thesis: that a small number of fundamental control points in red-blood-cell biology — heme biosynthesis and iron homeostasis, mediated by hepcidin — can be pharmacologically tuned in either direction to treat a wide spectrum of haematologic disease. The company operates an in-licensing-and-develop model rather than a discovery-platform model, having assembled its three clinical assets from Roche (bitopertin), AbbVie (selcodebart/DISC-0974 and DISC-0998) and Mabwell Therapeutics (DISC-3405). It has no products approved and no revenue. Its near-term valuation is dominated by a single binary: the Q4 2026 topline readout of the Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria, which follows a February 2026 Complete Response Letter. Behind that sits a genuine second act in myeloproliferative neoplasms. With approximately $718 million of liquidity at 30 June 2026 and runway into 2029, Disc is unusually well-capitalised for its stage.


What the company does. Disc Medicine discovers, in-licenses, develops and intends to commercialise novel therapeutics for serious haematologic diseases. In the company's own words, repeated verbatim in every press release and in the Compensation Discussion and Analysis of the 2026 proxy statement: Disc Medicine is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis.

Independent characterisation. Disc is best understood not as a discovery platform company but as a mechanism-directed asset aggregator with deep domain expertise in a single organ system. Management — drawn heavily from Acceleron Pharma, which built a comparable franchise around TGF-β superfamily biology in haematology before its $11.5 billion sale to Merck — has applied a repeatable playbook: identify a de-risked or partially de-risked molecule whose originator has deprioritised it, secure global rights at modest upfront cost with back-loaded milestones, and redirect it into a rare or under-served haematologic indication where the biology is mechanistically obvious and the regulatory path is short.

All three clinical assets were sourced this way. Bitopertin is a glycine transporter 1 (GlyT1) inhibitor that Roche advanced through large schizophrenia trials — generating a safety database of more than 4,000 clinical trial participants — before abandoning the CNS indication; Disc licensed it in May 2021 and repositioned it against erythropoietic porphyrias, where reducing glycine supply to developing erythroblasts throttles the accumulation of the toxic photoactive intermediate protoporphyrin IX (PPIX). Selcodebart (DISC-0974), an anti-hemojuvelin monoclonal antibody in-licensed from AbbVie, suppresses hepcidin to liberate iron in anaemia of inflammation. DISC-3405, an anti-TMPRSS6 (matriptase-2) monoclonal antibody in-licensed from Mabwell Therapeutics in January 2023, does the mirror image — inducing hepcidin to restrict iron in diseases of excess erythropoiesis or iron overload. The elegance of the portfolio is that DISC-0974 and DISC-3405 are pharmacological opposites acting on the same axis, giving Disc coverage of both hepcidin-deficient and hepcidin-excess disease states.

Business model and revenue model. Disc has generated no product, service, subscription or licensing revenue in any fiscal year reported. Its consolidated statements of operations show no revenue line whatsoever for FY2021 through FY2025 and for the six months ended 30 June 2026. The company is financed entirely by equity issuance, supplemented by a term-loan facility from Hercules Capital. The intended revenue model is direct commercialisation: Disc retains worldwide rights to bitopertin and has already built marketing, market access, medical science liaison and field sales infrastructure in the United States in anticipation of launch, a build-out the compensation committee credited as a 2025 corporate achievement. One small out-licensing arrangement exists — a December 2024 out-license of legacy Gemini intellectual property to Oak Bay Biosciences, Inc. — but it is immaterial to the investment case.

Value chain position. Disc occupies the clinical development and (prospectively) commercial layers only. It owns no manufacturing. Drug substance and drug product are produced by contract development and manufacturing organisations; the 2025 corporate goals explicitly include "initiated CMC technology transfer to Phase 3 CDMO" for both DISC-0974 and DISC-3405, confirming an outsourced supply chain. Clinical trials are run through contract research organisations, a dependency the company identifies as a risk factor. Upstream, Disc is a licensee dependent on Roche, AbbVie and Mabwell for underlying rights; downstream, if approved, bitopertin would be distributed through specialty pharmacy and centre-of-excellence channels typical of ultra-rare disease.

Customer types and end-markets. Ultimately: haematologists, hepatologists and dermatologists treating protoporphyria at porphyria centres of excellence; haematologist-oncologists treating myelofibrosis and polycythemia vera; and, in later-stage pipeline ambitions, gastroenterologists (anaemia of inflammatory bowel disease) and sickle cell disease specialists. Payers are commercial insurers and CMS in the US, and national reimbursement bodies in Europe. Management commentary at the Wells Fargo healthcare conference in September 2026 indicated a launch strategy focused on engaged, diagnosed patients and centres of excellence — the classic ultra-orphan concentration play.

Strategy

Stated strategy — verbatim themes. The corporate positioning statement repeated in every filing is the strategic thesis in miniature: "building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis." Three words in that sentence carry the strategy. Portfolio — Disc is explicitly not a single-asset company and resists being valued as one. Fundamental biological pathways — the company selects targets where the mechanism is causally upstream of the disease rather than symptomatic. Wide spectrum — each mechanism is intended to franchise across multiple indications rather than serve one.

Management's own framing of the 2025–2026 arc, from the January 2026 objectives release: "2025 was a transformative year for Disc, marked by strong execution across our portfolio and meaningful progress toward becoming a fully integrated clinical and commercial organization." And, looking forward: "We are preparing to execute a successful US launch of bitopertin for EPP while continuing enrollment in the global APOLLO confirmatory study." That second statement has since been overtaken by the CRL. The revised framing, from the September 2026 RESTORE-PV release, marks a deliberate rebalancing: "we have strengthened our commitment to hematologic oncology and now have two programs advancing toward potential pivotal development in myeloproliferative neoplasms."

That sentence is the single most strategically significant piece of management commentary in the last eighteen months. It signals that Disc is repositioning from an ultra-rare-disease company with an oncology option into a myeloproliferative neoplasm company with an ultra-rare-disease asset. The audience for that message is investors who marked the stock down on the CRL.

Announced strategic initiatives, last 24 months.

Sustainability, ESG and cost programmes. No emissions targets, sustainability-linked initiatives, formal ESG programme or announced cost-reduction programme have been disclosed. There has been no restructuring or workforce reduction following the CRL.

Medium-term financial targets and guidance. Disc provides no revenue, margin or earnings guidance — appropriate for a pre-revenue company. The only recurring quantitative guidance is cash runway, currently "into 2029" based on the 30 June 2026 position. Operational guidance as of the Q2 2026 report: APOLLO topline in Q4 2026; CRL response submission and an FDA decision by mid-2027; additional RALLY-MF data in Q4 2026 with an end-of-Phase-2 FDA meeting by year-end; RESTORE-PV update and Phase 1b SCD initial data by end of 2026; DISC-0974 IBD initial data in 2027; and the prospect of advancing two additional programmes into pivotal development in 2027.

Products & Services

Disc Medicine has no approved products and no commercial offerings anywhere in the world. Every asset described below is investigational. There is no disclosed pricing model for any candidate; pricing has not been announced for bitopertin notwithstanding launch preparations.

Bitopertin — oral GlyT1 inhibitor (heme synthesis modulator)

AttributeDetail
ModalitySmall molecule, orally administered, once daily
Target / mechanismInhibition of glycine transporter 1 (GlyT1), a membrane transporter expressed on developing red blood cells required to supply glycine for heme biosynthesis. Inhibition throttles the rate-limiting substrate supply, reducing accumulation of protoporphyrin IX (PPIX)
OriginIn-licensed from F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., May 2021; global rights
Legacy datasetRoche safety database of more than 4,000 clinical trial participants from prior CNS development
Lead indicationErythropoietic protoporphyria (EPP), including X-linked protoporphyria (XLP), in patients aged 12 and older
DesignationsUS Orphan Drug Designation (December 2022); US Rare Pediatric Disease Designation; EU orphan designation positive opinion (January 2023); Commissioner's National Priority Voucher (October 2025)
Regulatory statusNDA submitted September 2025; accepted with Priority Review under accelerated approval; Complete Response Letter issued 13 February 2026; Type A meeting completed June 2026; CRL response to be submitted following APOLLO topline, with an FDA decision expected by mid-2027
Clinical programmeBEACON (Phase 2, open-label, EPP/XLP); AURORA (Phase 2, randomised, double-blind, placebo-controlled, adult EPP); APOLLO (Phase 3, global, confirmatory, adults and adolescents, N=183, fully enrolled March 2026, topline Q4 2026); HELIOS (open-label long-term extension); EPP LIGHT (patient survey characterising life and health impact); NIH-collaborative study in Diamond-Blackfan Anemia
APOLLO co-primary endpointsAverage monthly time in light without pain during the last month of the six-month treatment period; and percentage change from baseline in whole-blood metal-free PPIX after six months
Latest efficacy signalHELIOS extension data presented at EHA June 2026 demonstrated sustained PPIX reductions, significant improvement in light-tolerance measures and favourable longer-term safety
Access programmeExpanded Access Programme launched 1 June 2026 in the US and select geographies
Target customerPatients with EPP/XLP treated at porphyria centres of excellence; prescribers are haematologists, hepatologists and dermatologists
Pricing model—

Selcodebart (DISC-0974) — anti-hemojuvelin monoclonal antibody (hepcidin suppression)

AttributeDetail
ModalityMonoclonal antibody, parenteral
Target / mechanismAnti-hemojuvelin (HJV). Suppresses hepcidin production, raising serum iron and mobilising iron for erythropoiesis in anaemia of inflammation
OriginIn-licensed from AbbVie
INNSelcodebart (international nonproprietary name adopted; company began using it in 2026 disclosures)
Lead indicationAnaemia of myelofibrosis (MF)
Other indicationsAnaemia of non-dialysis-dependent chronic kidney disease (NDD-CKD) — Phase 1b data presented 2025; anaemia of inflammatory bowel disease (IBD) — Phase 2 initiated Q1 2026, initial data expected 2027
DesignationsEU Orphan Drug Designation for myelofibrosis (announced Q2 2026)
Clinical statusPhase 2 RALLY-MF ongoing. Additional data anticipated Q4 2026; end-of-Phase-2 FDA meeting expected by year-end 2026
Headline efficacy (RALLY-MF, ASCO/EHA June 2026)Major anaemia response rate 56%; overall anaemia response rate 72% across evaluable patients; similar strong response rates across transfusion cohorts and with or without background JAK inhibitor therapy; durable overall anaemia responses across all subgroups
Intellectual propertyComposition-of-matter patent issued 2025 providing exclusivity to 2041, excluding potential extensions
Target customerHaematologist-oncologists managing transfusion-dependent and transfusion-independent anaemic MF patients, including those on JAK inhibitors
Pricing model—

DISC-3405 — anti-TMPRSS6 monoclonal antibody (hepcidin induction)

AttributeDetail
ModalityMonoclonal antibody, subcutaneous
Target / mechanismAnti-TMPRSS6 (transmembrane serine protease 6, matriptase-2). Increases endogenous hepcidin production and suppresses serum iron, restricting iron availability to the bone marrow
OriginIn-licensed from Mabwell Therapeutics, January 2023 (formerly MWTX-003); rights outside Greater China
Lead indicationPolycythemia vera (PV)
Second indicationSickle cell disease (SCD) — Phase 1b initiated Q4 2025; initial data expected Q4 2026
Clinical status (PV)RESTORE-PV, Phase 2 multi-centre open-label, N=40 (Cohort A n=20 dosed at 300 mg subcutaneously every two weeks; Cohort B n=20, of whom 18 dosed, every four weeks). Design: 4–12 week observation, 12-week dose escalation, 20 weeks at target dose, up to 20 further weeks. Fully enrolled Q2 2026; initial data presented 9–10 September 2026
Headline efficacy (RESTORE-PV, Cohort A, n=13 completing 26 weeks)Mean total phlebotomy events fell from 4.0 per 26 weeks at baseline to 0.6 per 26 weeks post-Day 1 (p<0.0001); 61.5% of participants entirely phlebotomy-free through 26 weeks; of those completing the first maintenance period (weeks 12–32, n=9), 77.8% phlebotomy-free; mean haematocrit maintained stably below 45% through week 26; dose-proportional PK with hepcidin elevation, serum iron reduction and ferritin increase; improvement in symptom burden
SafetyGenerally well tolerated; adverse events consistent with underlying disease; low rate of mild, self-limited injection-site reactions across both cohorts
Positioning claimFirst monoclonal antibody targeting TMPRSS6 to demonstrate phlebotomy reduction in PV
Target customerHaematologist-oncologists treating phlebotomy-dependent PV; PV affects approximately 150,000 patients in the US with similar prevalence in Europe
Pricing model—

DISC-0998 and early-stage programmes

AttributeDetail
DISC-0998Anti-hemojuvelin antibody in-licensed from AbbVie alongside DISC-0974; disclosed on the company pipeline page. Development status not currently highlighted in quarterly disclosures; treated as a back-up/next-generation asset. Detailed status not publicly disclosed
Undisclosed new programmeThe 2025 corporate goals record "Initiated IND-enabling studies for new program" under Certain Early-Stage Development, weighted at 4% of goals. Target and indication not publicly disclosed
Legacy Gemini assetsComplement-pathway assets from Gemini Therapeutics (e.g. GEM103) were discontinued pre-merger; residual intellectual property out-licensed to Oak Bay Biosciences in December 2024

Financial Narrative

Currency: USD. Fiscal years ended 31 December. Sources: FY2022 earnings release (FY2021, FY2022), FY2025 earnings release and Form 10-K (FY2023, FY2024, FY2025).

Balance sheet

Accumulated deficit for FY2024 is as disclosed in the FY2024 Form 10-K ($298.0 million); FY2025 is derived by adding the FY2025 net loss of $212.184 million, giving approximately $510.2 million. Non-current liabilities are used as a proxy for the Hercules term loan carrying value; the FY2025 10-K does not break out non-current liabilities in the summary balance sheet released with earnings, and a portion may relate to non-debt items. Goodwill and intangibles are recorded at nil: the Gemini transaction was accounted for as a reverse recapitalisation rather than a business combination, and all in-licensing payments have been expensed to R&D.

Cash flow

Dividends paid and buybacks are genuinely nil: Disc has never declared a dividend and has no repurchase authorisation. FY2022 equity proceeds combine $89.5 million net from the Gemini merger with the $53.5 million concurrent financing. FY2023 reflects the $62.5 million registered direct offering. FY2024 debt reflects $27.6 million of net proceeds received under the Hercules Loan Agreement through 31 December 2024. FY2025 equity reflects the January ($243.3 million net) and October ($211.0 million net) underwritten offerings.

Commentary on trends, inflections and drivers

Expense trajectory. The defining financial fact of Disc Medicine over five years is the 6.8-fold increase in R&D expense from $25.2 million in FY2021 to $170.6 million in FY2025, and the 11.3-fold increase in G&A/SG&A from $5.8 million to $65.4 million over the same period. Three distinct inflections are visible. The first, in FY2023, reflects the transition from a single Phase 2 programme to a multi-asset clinical portfolio — R&D more than doubled from $33.4 million to $69.3 million as AURORA, BEACON and two DISC-0974 Phase 1b/2 studies ran concurrently. The second, in FY2025, is the largest: R&D rose 76% year over year, driven by the initiation of the Phase 3 APOLLO trial, bitopertin registrational-scale drug manufacturing, the RALLY-MF Phase 2 study, initiation of two DISC-3405 patient studies, increased headcount, and $23.0 million of licence milestone payments ($10.0 million to Roche on APOLLO initiation, $10.0 million to Mabwell on first DISC-3405 patient dosing, $3.0 million to AbbVie on first DISC-0974 Phase 2 patient dosing). The third inflection is in SG&A, which nearly doubled in FY2025 to $65.4 million as Disc built marketing, market access, medical science liaison and field sales organisations in anticipation of a bitopertin launch.

The commercial-build overhang. The SG&A build was undertaken on the assumption of a 2026 launch, an assumption the February 2026 CRL invalidated for at least fifteen months. H1 2026 SG&A of $41.8 million against H1 2025 of $27.3 million shows the organisation has not been substantially unwound — the company has continued to carry launch-ready commercial infrastructure through a period in which no product can be sold. Management has framed this as retained optionality. It is nonetheless a real cash cost of approximately $80 million annualised for a capability that generates nothing until at least mid-2027. Notably, Q2 2026 R&D of $46.9 million was essentially flat against Q2 2025's $46.3 million despite portfolio expansion, because the prior-year quarter included the $10.0 million Roche milestone and because bitopertin manufacturing costs have declined. Underlying R&D growth is therefore steeper than the headline suggests.

Other income. Interest and investment income has become a material offset, rising from a $5.0 million net expense in FY2021 to $24.2 million of net income in FY2025, reflecting the growth of the marketable securities portfolio. At H1 2026 run-rate, other income of $11.7 million annualises to roughly $23 million, partially offset by interest expense on the Hercules facility. This income is a direct function of the cash balance and rate environment and will decline as the cash is consumed.

Balance sheet and funding. Disc has been an opportunistic and, so far, well-timed equity issuer. It raised $243.3 million net in January 2025 into strength following the successful Type C meeting, and $211.0 million net in October 2025 immediately after receiving the CNPV — the two most favourable windows of the past two years. Both raises were completed before the February 2026 CRL. The result is a balance sheet carrying $717.7 million at 30 June 2026 with only modest debt, giving runway into 2029 and, critically, removing financing risk from the APOLLO readout. Share count has grown from 22.3 million weighted-average in FY2023 to 38.6 million in H1 2026, dilution of roughly 73% over two and a half years — the price of that de-risking.

The increase in non-current liabilities from $30.4 million at 31 December 2025 to $60.5 million at 30 June 2026 indicates an incremental draw of approximately $30 million under the Hercules facility during H1 2026, consistent with the option to draw an additional $80.0 million on or before 15 December 2026. Cash declined only $73.4 million in H1 2026 against a $123.0 million net loss, the gap bridged by non-cash stock compensation and the debt draw.

Cash burn and runway sensitivity. Annualising H1 2026 operating expenses gives roughly $269 million of gross spend. Against $717.7 million of liquidity plus up to $170 million of undrawn Hercules capacity, the "into 2029" guidance appears conservative if — and only if — the company does not add a further Phase 3 programme. The 30 July 2026 commentary that Disc could be "positioned to advance two more programs into pivotal-stage development in 2027" is precisely the scenario that would consume that cushion. Investors should read the runway guidance as contingent on the current development plan, not on the plan management has signalled it wants to pursue.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Operating Metrics (count) and Results by Segment

MetricFY2021FY2022FY2023FY2024FY2025

Reportable segments (count)

11111

Total revenue, all segments (USD Mn)

00000

Segment operating income (USD Mn)

-30.9-47.5-91.1-129.7-236.0

Segment operating margin (%)

00000

Segment Revenue

Programme unit2025 corporate goal weighting (%)2025 weighted actual performance (%)

Bitopertin Development

3579

DISC-0974 Development

2520

DISC-3405 Development

1515

Certain Early-Stage Development

42

Finance & Company Building

2129

Total

100145

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (USD Mn)

00000

Gross profit (USD Mn)

00000

Research and development expense (USD Mn)

25.17033.43769.26496.671170.640

General and administrative / SG&A expense (USD Mn)

5.76314.03821.86133.04965.382

Total operating expenses (USD Mn)

30.93347.47591.125129.720236.022

Operating income / loss from operations (USD Mn)

-30.933-47.475-91.125-129.720-236.022

EBITDA (USD Mn, approximated as operating loss; D&A immaterial and not separately disclosed)

-30.9-47.5-91.1-129.7-236.0

Other income (expense), net (USD Mn)

-5.0360.64814.79520.71824.199

Pre-tax income (USD Mn)

-35.969-46.827-76.330-109.002-211.823

Income tax expense (USD Mn)

000.0990.3550.361

Net income / loss (USD Mn)

-35.969-46.827-76.429-109.357-212.184

EPS basic and diluted (USD)

-40.95-45.05-3.42-3.96-6.01

Weighted-average shares outstanding (millions)

0.8781.03922.31627.60635.296

Dividends per share (USD)

00000

Gross margin (%)

00000

Operating margin (%)

00000

EBITDA margin (%)

00000

Net margin (%)

00000

Revenue CAGR FY2021-FY2025 (%)

00000

Balance Sheet

MetricFY2021FY2022FY2023FY2024FY2025

Cash, cash equivalents and marketable securities (USD Mn)

88.036194.6110489.881791.152

Other current assets (USD Mn)

2.4483.88003.73412.746

Total current assets (USD Mn)

90.484198.4910493.615803.898

Non-current assets (USD Mn)

1.9271.71403.1582.981

Total assets (USD Mn)

92.411200.2050496.773806.879

Current liabilities (USD Mn)

13.42422.578023.31636.641

Non-current liabilities (USD Mn)

1.3341.027029.87030.412

Total liabilities (USD Mn)

14.75823.605053.18667.053

Convertible preferred stock (USD Mn)

141.8560000

Total stockholders' equity / (deficit) (USD Mn)

-64.203176.6000443.587739.826

Working capital (USD Mn, derived)

77.060175.9130470.299767.257

Total debt, short-term portion (USD Mn)

00000

Total debt, long-term portion — Hercules term loan (USD Mn, approximated by non-current liabilities)

00029.87030.412

Net debt / (net cash) (USD Mn, derived)

-88.036-194.6110-460.011-760.740

Goodwill and intangible assets (USD Mn)

00000

Accumulated deficit (USD Mn)

000298.0510.2

Returns & Leverage Ratios

MetricFY2021FY2022FY2023FY2024FY2025

Net cash used in operating activities (USD Mn)

00000

Capital expenditure (USD Mn)

00000

Free cash flow (USD Mn)

00000

Dividends paid (USD Mn)

00000

Share buybacks (USD Mn)

00000

Net equity proceeds raised (USD Mn)

0143.062.50454.4

Net debt proceeds drawn (USD Mn)

00027.60

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2021FY2022FY2023FY2024FY2025

Return on equity (%, derived on average equity)

000-35.3-35.9

Return on assets (%, derived on average assets)

0-32.00-31.4-32.6

Return on invested capital (%)

00000

Current ratio (x)

6.748.79021.1721.94

Debt to equity (x)

0000.070.04

Net debt to EBITDA (x)

2.854.1003.553.22

Interest coverage (x)

00000

Asset turnover (x)

00000

Cash conversion cycle (days)

00000

Income Statement and Per-Share Data (H1 2025–Q2 2026)

MetricQ2 2025Q2 2026H1 2025H1 2026

Research and development expense (USD Mn)

46.31946.93374.08292.837

Selling, general and administrative expense (USD Mn)

15.09118.14227.27441.762

Total operating expenses (USD Mn)

61.41065.075101.356134.599

Loss from operations (USD Mn)

-61.410-65.075-101.356-134.599

Other income, net (USD Mn)

6.2155.61212.19511.683

Net loss (USD Mn)

-55.247-59.532-89.332-123.036

EPS basic and diluted (USD)

-1.58-1.54-2.61-3.19

Weighted-average shares (millions)

35.02538.68634.17938.589

Balance Sheet (31 Dec 2025–30 Jun 2026)

Balance sheet item31 Dec 202530 Jun 2026

Cash, cash equivalents and marketable securities (USD Mn)

791.152717.746

Total current assets (USD Mn)

803.898732.761

Total assets (USD Mn)

806.879735.071

Current liabilities (USD Mn)

36.64130.360

Non-current liabilities (USD Mn)

30.41260.547

Total liabilities (USD Mn)

67.05390.907

Total stockholders' equity (USD Mn)

739.826644.164

Geographic Revenue

RegionFY2023FY2024FY2025

Americas revenue (USD Mn)

000

EMEA revenue (USD Mn)

000

APAC revenue (USD Mn)

000

Total revenue (USD Mn)

000

Valuation Snapshot

MetricValueAs of

Closing price (USD)

70.06

11 Sept 2026

Day change (%)

-5.50

11 Sept 2026

After-hours price (USD)

71.00

11 Sept 2026

Previous close (USD)

74.14

10 Sept 2026

Day's range (USD)

69.28 – 75.00

11 Sept 2026

52-week range (USD)

40.00 – 99.50

Trailing twelve months

Market capitalisation (USD Bn)

2.69

11 Sept 2026

Market capitalisation change (%)

+29.1

Year on year

Shares outstanding (millions)

38.39

Latest

Average daily volume (shares)

Approximately 350,000 – 630,000

Recent periods

Beta

2.05

Latest

Exchange

Nasdaq Global Market

—

Capital Markets Data (USD) and Capital Markets Data

MetricFY2022FY2023FY2024

Disc Medicine cumulative TSR, indexed to 100 (USD)

64.58187.53205.84

Peer group cumulative TSR, indexed to 100 (USD)

88.4891.7890.52

Net loss (USD Mn)

-46.827-76.429-109.357

Capital Markets

MetricDisc MedicineBasis

Price to book (x)

Approximately 4.2

$2.69 billion market capitalisation over $644.2 million book equity at 30 June 2026

Enterprise value (USD Bn, derived)

Approximately 2.03

$2.69 billion market capitalisation less $717.7 million cash plus approximately $60 million total liabilities of a debt character

Cash per share (USD, derived)

Approximately 18.70

$717.7 million over 38.39 million shares

Enterprise value per share (USD, derived)

Approximately 52.90

—

Valuation Snapshot — Number of covering analysts

MetricValue

Number of covering analysts

13

Consensus Rating Details

Consensus ratingStrong Buy

Mean twelve-month price target (USD)

102.58

Implied upside from $70.06 (%)

+46.4

Prior consensus target (mid-2025) (USD)

95.73 – 98.30

Morgan Stanley

Overweight; target raised to $90 from $85 in August 2026, having been raised from $80 to $85 in June 2026

TD Cowen

Buy (August 2025)

Q2 2026 EPS actual versus consensus (USD)

-1.54 versus -1.77 (beat by $0.23)

Q2 2025 EPS actual versus consensus (USD)

-1.58 versus -1.17 (miss by $0.41)

Capital Markets — Dividend policy

ItemStatus

Dividend policy

No dividend has ever been declared or paid. No dividend is contemplated. The compensation programme explicitly does not pay dividends or dividend equivalents on unearned shares

Share repurchase authorisation

None. No buyback has ever been authorised or executed

Moody's rating

Not rated

S&P rating

Not rated

Fitch rating

Not rated

Total debt facility

Hercules Capital term loan facility of up to $200 million

Drawn as of 31 Dec 2025

Approximately $30 million (proxied by non-current liabilities)

Estimated drawn as of 30 Jun 2026

Approximately $60 million, inferred from the increase in non-current liabilities from $30.412 million to $60.547 million

Available capacity

Up to $80.0 million drawable on or before 15 December 2026; up to $65.0 million further subject to performance milestones; a final $25.0 million subject to conditions

Interest rate

Floating: greater of 8.25% or Prime plus 1.75%, payable monthly in cash

Maturity

1 December 2029

Debt maturity profile

Single bullet maturity at 1 December 2029. No other debt outstanding. No convertible securities outstanding. Pre-funded warrants issued in the January and October 2025 offerings remain outstanding in part

Analyst Conclusions

Management guidance

MilestoneTiming guided
APOLLO Phase 3 topline, bitopertin in EPPQ4 2026
CRL response submissionFollowing APOLLO topline; company has indicated by end of 2026
FDA decision on bitopertinBy mid-2027
Additional RALLY-MF data, selcodebart in MF anaemiaQ4 2026
End-of-Phase-2 FDA meeting, selcodebart in MF anaemia, and pivotal development plansBy year-end 2026
RESTORE-PV update, DISC-3405 in PVBy end of 2026
Initial Phase 1b data, DISC-3405 in sickle cell diseaseQ4 2026
Initial data, selcodebart Phase 2 in IBD anaemia2,027
Potential advancement of two additional programmes into pivotal development2,027

Disc provides no financial guidance beyond cash runway. As of the Q2 2026 report, the company expects its $717.7 million of cash, cash equivalents and marketable securities to fund operational plans into 2029. Operationally, management has guided to:

Consensus growth expectations

The observable consensus datapoints are a Strong Buy rating from thirteen analysts and a mean twelve-month price target of $102.58, implying 46.4% upside from the 11 September 2026 close. Consensus expects continued losses through at least FY2027; the Q2 2026 consensus EPS estimate of −$1.77 against an actual of −$1.54 indicates the street is modelling quarterly losses in the $1.50–$1.80 per share range.

Bull case

1. APOLLO succeeds and delivers traditional approval, not accelerated approval — a strictly better outcome than the January 2026 base case. The June 2026 Type A meeting secured FDA alignment that a successful APOLLO can support traditional approval. Traditional approval eliminates post-marketing confirmatory obligations, produces a stronger label, and materially improves the payer negotiation. The trial is fully enrolled at N=183, completed ahead of schedule, and passed a blinded sample-size re-estimation without adjustment — three independent indications of execution quality. The FDA has already conceded the pharmacology; the remaining question is whether a demonstrated PPIX reduction translates into measurable light tolerance, and the HELIOS open-label extension presented at EHA in June 2026 showed exactly that translation, with sustained PPIX reduction accompanied by significant improvement in light-tolerance measures.

2. The myeloproliferative neoplasm franchise is being systematically under-credited. With roughly $2.0 billion of enterprise value and the substantial majority of it attributed to bitopertin, the market is assigning modest value to two programmes that have both now produced clinical proof of concept. Selcodebart delivered a 56% major and 72% overall anaemia response rate in MF, effective regardless of transfusion status or JAK inhibitor use, with composition-of-matter protection to 2041. DISC-3405 reduced mean phlebotomy events from 4.0 to 0.6 per 26 weeks with 61.5% of patients entirely phlebotomy-free, in a PV population of approximately 150,000 US patients. Both are heading to pivotal-stage decisions within twelve months. Management's September 2026 language — two programmes advancing toward pivotal development in myeloproliferative neoplasms — is a deliberate repositioning of the equity story away from single-asset dependence, and it is grounded in data rather than aspiration.

3. The financing risk that usually accompanies a binary readout has been eliminated. $717.7 million of liquidity, guided runway into 2029, up to $170 million of undrawn non-dilutive capacity, a single bullet debt maturity in December 2029, and net cash covering roughly 27% of the current share price. Management raised $454.4 million in 2025 at prices well above the post-CRL trough — before the CRL. Disc will not be a forced seller of equity at any point before the mid-2027 decision, which is a structurally unusual position for a company facing a Phase 3 readout and materially changes the risk-reward asymmetry.

Bear case

1. The CRL revealed a fundamental evidentiary problem that APOLLO may not solve. The FDA did not question whether bitopertin lowers PPIX. It questioned whether lowering PPIX makes patients better. AURORA and BEACON, both of which measured sunlight-exposure endpoints, failed to demonstrate the association. APOLLO measures the same category of endpoint in the same disease with the same drug. The trial is larger and better powered, but the hypothesis under test is the one that has already failed to produce a convincing signal twice. Meanwhile, dersimelagon — a mechanistically inferior, purely photoprotective agent — has already demonstrated a statistically significant placebo-adjusted improvement in daily sunlight exposure of 23.19 minutes in Phase 3 and filed its NDA in June 2026. If the competitor can hit the clinical endpoint and Disc cannot, the mechanistic superiority argument becomes commercially irrelevant.

2. Every market Disc is entering has acquired a well-capitalised incumbent within the last twelve months. In EPP, LEO Pharma paid up to $435 million for dersimelagon in August 2026 and brings a dedicated dermatology commercial organisation to a market where the existing incumbent, Clinuvel, generates over $100 million with an eight-weekly implant. In PV, the FDA approved rusfertide on 28 August 2026 with a 76.9% Phase 3 response rate, giving Takeda first-mover status in the hepcidin pathway before DISC-3405 has completed Phase 2 — and Silence Therapeutics' divesiran hit its Phase 2 primary endpoint two weeks earlier with an 88% versus 19% response and a dosing interval of twelve weeks against DISC-3405's two to four. Disc is now third to the TMPRSS6 target and behind on both approval timing and convenience. Approximately $170 million of annual R&D is being deployed into three markets where someone else got there first.

3. The cost base has been built for a company that does not yet exist, and the runway guidance assumes a plan management has said it will not follow. SG&A doubled to $65.4 million in FY2025 and ran at $41.8 million in H1 2026, sustaining marketing, market access, MSL and sales organisations for a product that cannot generate a dollar before mid-2027 at the earliest — and never, if APOLLO misses. No restructuring has been announced. Total H1 2026 operating expenses of $134.6 million annualise to $269 million. The "runway into 2029" figure holds only if Disc does not advance additional programmes to pivotal stage — precisely what management stated in July 2026 it intends to do in 2027. Two additional Phase 3 programmes would compress the runway substantially, and would have to be funded from a share count that has already grown 73% in two and a half years.

Key catalysts and monitorables — next twelve months

TimingCatalystWhy it matters
Q4 2026APOLLO Phase 3 topline, bitopertin in EPP (N=183)The single determinant of the majority of enterprise value. Watch both co-primary endpoints — average monthly time in light without pain in the last month of the six-month period, and percentage change in whole-blood metal-free PPIX. The second is near-certain; the first is the whole question
Q4 2026Additional RALLY-MF data, selcodebartDurability and depth of anaemia response across a larger dataset
By year-end 2026End-of-Phase-2 FDA meeting, selcodebart in MF anaemia, plus disclosed pivotal designEstablishes the size, endpoint and cost of the second Phase 3 programme — and therefore the true runway
Q4 2026Initial Phase 1b data, DISC-3405 in sickle cell diseaseSecond indication; a positive result meaningfully broadens the DISC-3405 franchise beyond a crowded PV market
By end-2026RESTORE-PV Cohort B data and Cohort A updateQ4-weekly dosing performance in Cohort B is the direct answer to divesiran's twelve-week interval
End-2026 / early 2027CRL response submissionConfirms the regulatory clock restart
~Mid-2027FDA decision on bitopertinApproval or a second rejection
OngoingFDA action on dersimelagonAn approval would establish a marketed oral competitor before bitopertin can launch
OngoingRusfertide launch trajectoryReal-world uptake, dosing tolerability and payer treatment of a weekly injection will define the commercial opening for DISC-3405
OngoingDivesiran Phase 3 initiation and designDetermines the competitive timeline in PV
OngoingHercules drawdown behaviourFurther draws signal either opportunism or funding pressure; the $80 million option expires 15 December 2026
OngoingSG&A trajectoryWhether the commercial organisation is retained, expanded or trimmed is the clearest read on management's internal confidence in APOLLO
OngoingAny outbound partnershipEx-US bitopertin rights or the CKD/IBD indications of selcodebart would be the natural candidates and would provide external valuation validation
OngoingSecurities litigation riskNo class action has been filed post-CRL; the window has not closed

Analyst verdict

Disc Medicine is a well-run company that has made one large bet, had it partially rejected, and been given a second and arguably better chance to make it. That is the whole investment case, and it should be evaluated as such rather than as a diversified pipeline story.

The February 2026 CRL was the most benign form of rejection available. The FDA accepted the pharmacology outright — bitopertin lowers protoporphyrin IX, and the biology is plausible — and rejected only the inference from biomarker to benefit. The June Type A meeting then converted the setback into an upgrade: a successful APOLLO now supports traditional approval rather than the accelerated approval originally sought, eliminating confirmatory obligations. Management's execution through this period has been genuinely good. APOLLO enrolled ahead of schedule at N=183, the sample-size re-estimation required no change, and $454.4 million was raised at favourable prices before the bad news arrived. The company enters its defining readout with $717.7 million, no financing pressure, and a clean debt profile maturing in 2029.

Against that, three things should temper enthusiasm. APOLLO tests the same hypothesis that two prior trials failed to establish convincingly. Every one of Disc's three markets acquired a well-funded incumbent in the last twelve months — LEO/Tanabe in EPP, Takeda in PV, and Silence close behind with better dosing. And roughly $80 million of annualised SG&A is being spent on a commercial organisation with nothing to sell.

The myeloproliferative neoplasm franchise is real and under-priced, but it is eighteen to twenty-four months from pivotal data. Between now and Q4 2026, this is a single-catalyst equity trading at a 46% discount to consensus target with a beta of 2.05. Position sizing, not conviction, is the operative question. Rating stance: high-conviction, high-variance; not a core holding.


End of dossier. Prepared 12 September 2026 from publicly available sources. Where sources conflict — notably institutional ownership percentages and Clinuvel's reporting currency — both readings are presented and the discrepancy noted. This document is for informational purposes and is not investment advice.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleOfficer sinceAgeSelected prior rolesEducation

John Quisel, J.D., Ph.D.

President, Chief Executive Officer and Director

202054

Acceleron Pharma (2006–2020), latterly Chief Business Officer; associate at Ropes & Gray and Foley Hoag; director of Gossamer Bio (Nasdaq: GOSS) since Nov 2023

A.B. Harvard; M.S. Stanford; Ph.D. MIT; J.D. Harvard Law School

Jean Franchi

Chief Financial Officer

202459

CFO of Replimune Group (2019–2023); CFO of Merrimack Pharmaceuticals (2017–2019); CFO of Dimension Therapeutics (2015–2017); CFO of Good Start Genetics (2012–2015); Sanofi 1995–2011, including SVP Corporate Finance

B.B.A. Hofstra University

Pamela Stephenson, M.P.H.

Chief Commercial Officer

202458

Chief Commercial Officer, Albireo Pharma (2019–2023); Vice President, Vertex Pharmaceuticals (2008–2019); Pfizer (1998–2008)

B.A. Brown University; M.P.H. Boston University School of Public Health

William (Will) Savage, M.D., Ph.D.

Chief Medical Officer

202152

VP, Head of Clinical Development at Disc (2020–2021); Senior Medical Director, Magenta Therapeutics; Global Clinical Development Lead, Hematology at Shire/Takeda; Assistant Professor of Pathology, Harvard Medical School/Brigham and Women's

B.A. Columbia; M.D. (honours in research) Weill Cornell; Ph.D. Johns Hopkins Bloomberg School of Public Health

Jonathan Yu, M.B.A.

Chief Operating Officer

202145

Chief Business Officer at Disc (2021–2024); SVP Corporate Development (2020–2021); co-founder and VP Corporate Strategy, Finance and Operations at Qpex Biopharma; The Medicines Company (2013–2018); SR One, Acceleron, Johnson & Johnson

A.B. Harvard College; M.B.A. Wharton

Rahul Khara, Pharm.D., J.D.

Chief Legal Officer and Secretary

202144

General Counsel at Disc (2021–2024); VP Legal and Chief Compliance Officer, Acceleron (2018–2021); Arnold & Porter; Sidley Austin

Pharm.D. Rutgers; J.D. University of Michigan Law School

Executive Leadership Team — Steve Caffé, M.D.

NameTitle

Steve Caffé, M.D.

Chief Regulatory Officer

Rahul Rajan Kaushik, Ph.D.

Chief Technical Officer

Lisa Amaya Price

Chief Human Resources Officer

Hua Yang, Ph.D.

Chief Early Development Officer

Srikanth Venkatraman, Ph.D.

SVP, Head of Chemistry

Sonia Razzetti, Ph.D.

SVP, Quality

Joseph Beaulieu

SVP, Finance

Melanie Chin, Ph.D.

SVP, Clinical Development and Head of Medical Affairs

Board of Directors

NameRoleDirector sinceClassTerm expiresAgeIndependentPrincipal affiliation

Donald Nicholson, Ph.D.

Executive Chairman

2019

III

2,02968

Yes

Former CEO, Nimbus Therapeutics; ex-Merck; boards of Muna Therapeutics, Matchpoint Therapeutics, NodThera

John Quisel, J.D., Ph.D.

Director, President and CEO

2020

III

2,02954

No

Disc Medicine; board of Gossamer Bio

William White, M.P.P., J.D.

Director

2020

III

2,02953

Yes

Former EVP, CFO and Head of Corporate Development, Akero Therapeutics (to its acquisition by Novo Nordisk, Dec 2025); ex-Deutsche Bank, Citigroup, Goldman Sachs

Nadim Ahmed, M.S.

Director

2025

I

2,02758

Yes

President and CEO, Cullinan Therapeutics; former President, Hematology at Bristol Myers Squibb; former President, Global Hematology & Oncology at Celgene

Kevin Bitterman, Ph.D.

Director

2017

I

2,02749

Yes

Partner, Atlas Venture Life Science Advisors; founding CEO of Editas Medicine, Morphic Therapeutics and Visterra

Mark Chin, M.S., M.B.A.

Director

2021

II

2,02844

Yes

Partner, Avoro Capital; formerly Arix Bioscience, Longitude Capital, BCG, Gilead, Genentech

Georges Gemayel, Ph.D.

Director

2022

II

2,02865

Yes

Former interim CEO and Executive Chair, Gemini Therapeutics; former EVP, Genzyme; board of Supernus Pharmaceuticals; chair of GlycoEra

Liam Ratcliffe, M.D., Ph.D.

Director

2019

II

2,02862

Yes

Head of Biotechnology, Access Industries; formerly New Leaf Venture Partners; former Worldwide Head of Clinical R&D, Pfizer

Directors' Remuneration

CommitteeMembersChair2025 meetings

Audit

William White, Liam Ratcliffe, Mark Chin

William White (designated audit committee financial expert)

4

Compensation

Donald Nicholson, Georges Gemayel, Kevin Bitterman

Donald Nicholson

3

Nominating and Corporate Governance

Kevin Bitterman, Donald Nicholson, Liam Ratcliffe

Kevin Bitterman

1

Commercial (established July 2025)

Nadim Ahmed, Mark Chin, Georges Gemayel

Georges Gemayel

4

Directors' Remuneration (2024 base salary (USD)–2025 base salary (USD))

Executive2024 base salary (USD)2025 base salary (USD)Change (%)Target bonus (% of salary)

John Quisel

645,000695,0007.855

Jean Franchi

515,000531,0003.140

Pamela Stephenson

505,000520,0003.040

William Savage

505,000523,0003.640

Jonathan Yu

490,000507,0003.540

Directors' Remuneration by Executive

ExecutivePercent of target awarded (%)Bonus as % of base salaryBonus awarded (USD)

John Quisel

14579.75554,263

Jean Franchi

14558.00307,980

Pamela Stephenson

14558.00301,600

William Savage

14558.00303,340

Jonathan Yu

14558.00294,060

Directors' Shareholdings

ExecutiveStock options (#)Option value (USD)RSUs (#)RSU value (USD)Combined equity value (USD)

John Quisel

117,5054,441,04678,3374,285,8178,726,863

Jean Franchi

36,0001,360,60336,0001,969,5603,330,163

Pamela Stephenson

36,0001,360,60336,0001,969,5603,330,163

William Savage

36,0001,360,60324,0001,313,0402,673,643

Jonathan Yu

36,0001,360,60324,0001,313,0402,673,643

Directors' Remuneration (FY2022–FY2024)

MetricFY2022FY2023FY2024

CEO total compensation, Summary Compensation Table (USD)

1,831,265909,1009,065,924

CEO compensation actually paid (USD)

1,183,8785,226,0128,673,485

Average non-CEO NEO total compensation (USD)

841,2811,220,7783,827,045

Average non-CEO NEO compensation actually paid (USD)

690,9391,915,1484,301,978

Company total shareholder return, indexed (USD)

64.58187.53205.84

Peer group total shareholder return, indexed (USD)

88.4891.7890.52

Net loss (USD K)

-46,827-76,429-109,357

Major Shareholders

HolderShares% of classAs ofSource

AI DMI LLC (Access Industries / Len Blavatnik)

3,762,50710.80

15 Apr 2025

DEF 14A 2025

Entities affiliated with Atlas Venture Fund

2,551,2387.37

15 Apr 2025

DEF 14A 2025

FMR LLC (Fidelity)

2,259,4376.52

15 Apr 2025

DEF 14A 2025

RA Capital Healthcare Fund, L.P. / RA Capital Management, L.P.

2,228,9245.90

30 Dec 2025

Schedule 13G filed 7 Jan 2026; confirmed in DEF 14A 2026

Entities affiliated with Wellington Management Group LLP

1,995,4055.76

15 Apr 2025

DEF 14A 2025

BlackRock, Inc.

1,851,1715.35

15 Apr 2025

DEF 14A 2025

Entities affiliated with Frazier Life Sciences Management LP

1,754,8345.07

15 Apr 2025

DEF 14A 2025

Vanguard Group Inc.

1,448,059

~3.8

Q3 2025 13F

13F aggregator

Competitive Landscape

Key Competitors

CompetitorAssetMechanismStatus as of Sept 2026Relative positioning versus bitopertin

Clinuvel Pharmaceuticals (ASX: CUV)

SCENESSE (afamelanotide)

MC1R agonist; α-MSH analogue increasing eumelanin

Approved. FDA-approved 2019; EU and Australia approved. The only approved EPP therapy

Incumbent. Subcutaneous implant every eight weeks, adults only, US price historically cited at approximately $55,000 per implant, distributed through a limited network of specialty centres. Photoprotective, not disease-modifying — does not lower PPIX

Mitsubishi Tanabe Pharma / LEO Pharma

Dersimelagon (MT-7117)

Oral selective MC1R agonist

NDA submitted June 2026, under FDA review. Positive Phase 3 INSPIRE (n=165, aged 12+): placebo-adjusted LS mean increase in daily sunlight exposure before prodromal symptoms of 23.19 minutes at weeks 12–16 (p=0.004), rising to 29.64 minutes at week 16 in a supplementary analysis. Fast Track and Orphan Drug Designations. LEO Pharma acquired worldwide rights in August 2026 for up to $435 million in upfront and near-term milestones

The principal competitive threat. Oral, once daily, 50 mg and 100 mg, adolescents and adults, backed by a committed dermatology commercial organisation. Could reach the market before or around the same time as bitopertin. Crucially, it has demonstrated the clinical endpoint the FDA told Disc it had not yet demonstrated

Disc Medicine

Bitopertin

Oral GlyT1 inhibitor; heme synthesis modulation

CRL February 2026; APOLLO topline Q4 2026; decision expected mid-2027

Only asset addressing the root cause by reducing PPIX. If APOLLO succeeds, potential first disease-modifying therapy and the only one with a plausible claim on hepatobiliary complications. Currently behind dersimelagon on regulatory timing

Undisclosed developer

PORT-77

Not characterised in sources reviewed

Early development

Referenced in EPP clinical literature as an additional pipeline agent.

Alnylam Pharmaceuticals

GIVLAARI (givosiran)

siRNA targeting ALAS1

Approved for acute hepatic porphyria

Adjacent, not directly competing — different porphyria subtype — but establishes ALAS1/heme-pathway modulation as a validated commercial category and a potential future entrant into erythropoietic porphyrias

Key Competitors — GSK

CompetitorAssetMechanismStatusPositioning versus selcodebart

GSK

Ojjaara / Omjjara (momelotinib)

JAK1/JAK2/ACVR1 inhibitor

Approved for MF with anaemia

The incumbent anaemia-directed MF therapy. Selcodebart's demonstrated efficacy irrespective of concomitant JAK inhibitor use positions it as additive rather than competitive

Incyte

Jakafi (ruxolitinib)

JAK1/JAK2 inhibitor

Approved; MF standard of care

Causes or worsens anaemia in many patients — arguably creates the market selcodebart addresses

Keros Therapeutics (Nasdaq: KROS) / Takeda

Elritercept (KER-050)

Activin receptor ligand trap (TGF-β superfamily)

Licensed to Takeda in 2025; Keros retained economics via the collaboration. Keros restructured in 2025

The closest mechanistic competitor for MF anaemia outside the JAK class, now backed by Takeda's resources

Geron

RYTELO (imetelstat)

Telomerase inhibitor

Approved in lower-risk MDS; MF development ongoing

Adjacent; competes for the same haematologist prescribers

Bristol Myers Squibb

Reblozyl (luspatercept)

Erythroid maturation agent

Approved in MDS and beta-thalassemia; MF anaemia studied

The commercial template for the anaemia-of-haematologic-malignancy category

Disc Medicine

Selcodebart (DISC-0974)

Anti-hemojuvelin; hepcidin suppression

Phase 2 RALLY-MF; end-of-Phase-2 FDA meeting by year-end 2026

Major anaemia response 56%, overall response 72%; effective across transfusion cohorts and independent of JAK inhibitor use. Differentiated by mechanism — the only hepcidin-suppression approach in late-stage MF anaemia development

Key Competitors — Takeda / Protagonist Therapeutics

CompetitorAssetMechanismStatusPositioning versus DISC-3405

Takeda / Protagonist Therapeutics (Nasdaq: PTGX)

Rusfertide

Peptide hepcidin mimetic

FDA-approved 28 August 2026 on the basis of Phase 3 VERIFY (76.9% response rate weeks 20–32), plus Phase 2 REVIVE and the THRIVE long-term extension

The incumbent-to-be. First-in-class approval in the hepcidin pathway for PV. Weekly self-administered subcutaneous injection in Phase 3 — the vulnerability Disc is targeting

Silence Therapeutics (Nasdaq: SLN)

Divesiran (SLN124)

GalNAc-conjugated siRNA silencing TMPRSS6

Phase 2 SANRECO topline 10 August 2026: 88% response weeks 18–36 versus 19% placebo (n=48, phlebotomy-dependent); phlebotomy rate 0.2 versus 2.1 on placebo; primary endpoint met. Advancing to Phase 3 with every-12-week dosing

The same target as DISC-3405 by a different modality. Ahead of Disc in development and with a materially less frequent dosing interval. The most direct threat to DISC-3405's differentiation claim

Incyte

Jakafi (ruxolitinib)

JAK1/JAK2 inhibitor

Approved for PV inadequately controlled by hydroxyurea

Cytoreductive standard of care in second line

PharmaEssentia

BESREMi (ropeginterferon alfa-2b)

Pegylated interferon

Approved for PV

Disease-modifying cytoreductive alternative

Ionis Pharmaceuticals

Antisense targeting TMPRSS6

ASO

Early-stage

Third modality against the same target

Disc Medicine

DISC-3405

Anti-TMPRSS6 monoclonal antibody

Phase 2 RESTORE-PV initial data September 2026; update and further data by year-end

Third to the target across three modalities. Differentiators claimed: 300 mg subcutaneous every two or four weeks, fixed dosing, and antibody durability. Mean phlebotomy events fell from 4.0 to 0.6 per 26 weeks with 61.5% phlebotomy-free

Peer Comparison FY2025

MetricDisc Medicine (FY2025)Clinuvel PharmaceuticalsProtagonist TherapeuticsKeros Therapeutics

Revenue, most recent full year (USD Mn)

061.100

Revenue growth (%)

05.500

R&D expense, most recent full year (USD Mn)

170.613.200

R&D intensity, R&D as % of revenue (%)

021.600

Net margin (%)

0000

Market capitalisation (USD Bn, Sept 2026)

2.69000

Cash and investments, latest reported (USD Mn)

717.700257.6

Recent Developments

Litigation, regulatory actions, restructurings and layoffs: *

Company Snapshot

165

Employees

2022

Founded

Massachusetts, US

Headquarters

SWOT Analysis

Strengths

  • Balance sheet strength removes financing risk through the binary event. $717.7 million of cash, cash equivalents and marketable securities at 30 June 2026, with guided runway into 2029, plus up to $170 million of undrawn Hercules capacity. Disc will not be forced to raise equity before the mid-2027 FDA decision.
  • Capital raised at the right times. $243.3 million net in January 2025 after the successful Type C meeting and $211.0 million net in October 2025 immediately following the CNPV award — $454.4 million in total, all secured before the February 2026 CRL.
  • An unusually large legacy safety database for the lead asset. Roche generated safety data on more than 4,000 clinical trial participants with bitopertin, materially de-risking chronic-dosing safety for a molecule now targeted at lifelong use.
  • Mechanistic first-in-class positioning in EPP. Every approved or filed EPP competitor works by increasing photoprotective pigmentation. Bitopertin is the only candidate that lowers protoporphyrin IX — and the FDA itself conceded in the CRL that AURORA and BEACON provided sufficient evidence of that effect.
  • A genuine second franchise with clinical proof. RALLY-MF delivered a 56% major anaemia response rate and 72% overall anaemia response rate, with efficacy independent of transfusion status and of concomitant JAK inhibitor use — and selcodebart carries composition-of-matter protection to 2041.
  • Third asset now clinically validated. RESTORE-PV Cohort A showed mean phlebotomy events falling from 4.0 to 0.6 per 26 weeks (p<0.0001) with 61.5% of participants entirely phlebotomy-free — the first anti-TMPRSS6 antibody to demonstrate this.
  • Regulatory path upgraded post-CRL. The June 2026 Type A meeting secured alignment that a successful APOLLO could support traditional approval, not merely the accelerated approval originally sought — a better outcome than the pre-CRL base case, since it removes post-marketing confirmatory obligations.
  • Governance quality above small-cap norm. Seven of eight directors independent, chair and CEO roles separated, clawback policy in force, hedging and pledging prohibited, no single-trigger change-in-control benefits, no 280G gross-ups, and say-on-pay support of 99.24% in 2025.

Weaknesses

  • Extreme single-asset concentration. A substantial majority of the $2.69 billion market capitalisation rests on one Phase 3 topline in Q4 2026. The 52-week range of $40.00 to $99.50 quantifies how much of the equity is a binary.
  • No revenue in any fiscal year, ever. FY2021 through FY2025 and H1 2026 show a blank revenue line; cumulative accumulated deficit reached approximately $510 million at 31 December 2025.
  • Cost base grown ahead of any commercial reality. SG&A rose from $33.0 million in FY2024 to $65.4 million in FY2025 and ran at $41.8 million in H1 2026 alone, sustaining a launch organisation for a product that cannot be sold before mid-2027 at the earliest.
  • No proprietary discovery platform. All three clinical assets were in-licensed — bitopertin from Roche, selcodebart and DISC-0998 from AbbVie, DISC-3405 from Mabwell — leaving no renewable internal source of candidates and creating dependency on three separate licensors.
  • Permanent economic leakage to licensors. Roche is entitled to tiered royalties from the high single digits to the high teens on bitopertin net revenues plus up to $120.0 million of sales-threshold milestones; Mabwell to up to $275.0 million of commercial milestones; AbbVie to a low-single-digit royalty plus up to $87.5 million of net-sales milestones. Peak-year gross margin will be structurally below a comparable owned-asset company.
  • Dilution has been heavy. Weighted-average shares rose from 22.3 million in FY2023 to 38.6 million in H1 2026 — approximately 73% dilution in two and a half years.
  • No outbound partnership or external validation. Disc funds all three programmes and all indications alone, including CKD and IBD indications for selcodebart that lie outside any plausible internal commercial competence.
  • Incentive design rewarded process, not outcome. The 2025 bonus paid at 145% of target, driven in part by stretch goals for "achieved potential for accelerated NDA approval decision" (+30%) and "shifted operations to support potential accelerated commercial launch" (+14%) — both determined in December 2025 and both rendered moot by the CRL eight weeks later, with no clawback trigger.

Opportunities

  • Traditional approval carries a better commercial profile than accelerated approval. A traditional-approval label with confirmatory Phase 3 data behind it is materially stronger in payer negotiations and physician adoption than an accelerated approval on a surrogate endpoint.
  • A larger second market. PV affects approximately 150,000 patients in the US with similar European prevalence — orders of magnitude above EPP. Management now describes two programmes advancing toward pivotal development in myeloproliferative neoplasms.
  • Indication expansion at low incremental cost. Selcodebart is already in Phase 2 for IBD anaemia with data expected in 2027 and has Phase 1b data in NDD-CKD; DISC-3405 has a Phase 1b in sickle cell disease reading out in Q4 2026. Each additional indication leverages the same molecule, manufacturing and safety database.
  • The Expanded Access Programme as a commercial bridgehead. The EAP has placed bitopertin with prescribers and patients before approval, identifying the treatable population and building prescriber familiarity — and, per Clinuvel's own August 2026 commentary, already exerting competitive pressure on the incumbent.
  • European expansion. Selcodebart holds EU Orphan Drug Designation for myelofibrosis and bitopertin holds an EU orphan positive opinion, but no European filing has been announced. Ex-US rights are unencumbered and unmonetised.
  • Undrawn non-dilutive capacity. Up to $80.0 million available under the Hercules facility on or before 15 December 2026, with a further $65.0 million milestone-linked and $25.0 million conditional — funding a pivotal programme without equity issuance.
  • Strategic interest. A de-risked orphan asset, a validated second mechanism, and $718 million of cash constitute a recognisable acquisition profile. Two current or recent Disc directors served on the boards of Akero Therapeutics (acquired by Novo Nordisk, December 2025) and Ventyx Biosciences (acquired by Eli Lilly, March 2026). This is contextual observation, not evidence of any process.
  • The undisclosed fourth programme. IND-enabling studies were initiated in 2025 for a new internally originated candidate — the first evidence of organic pipeline generation.

Threats

  • APOLLO failure is a near-total loss of the bitopertin thesis. The FDA has stated it needs APOLLO. A miss on the light-tolerance co-primary endpoint would leave the CRL unanswerable and strand the entire commercial build.
  • Dersimelagon may reach the EPP market first with the evidence Disc lacks. Mitsubishi Tanabe's oral MC1R agonist met its Phase 3 endpoints in INSPIRE (placebo-adjusted 23.19 minutes, p=0.004), filed its NDA in June 2026, and was acquired by LEO Pharma in August 2026 for up to $435 million — bringing a dedicated dermatology commercial organisation.
  • Rusfertide's approval reshapes PV before DISC-3405 finishes Phase 2. FDA approved rusfertide on 28 August 2026 with a 76.9% response rate in Phase 3 VERIFY. First-mover advantage in a hepcidin-pathway PV market now belongs to Takeda.
  • Divesiran's dosing interval is structurally superior. Silence Therapeutics' siRNA hit its Phase 2 primary endpoint in August 2026 (88% versus 19% response; phlebotomy rate 0.2 versus 2.1) and is advancing to Phase 3 with every-12-week dosing against DISC-3405's every two or four weeks.
  • Regulatory precedent risk on surrogate endpoints. The CRL established that the FDA will not accept PPIX reduction as a surrogate absent demonstrated correlation with clinical benefit — and that a Commissioner's National Priority Voucher accelerates review speed without lowering the evidentiary bar. This is a durable constraint on Disc's biomarker-led strategy.
  • Licensor dependency and termination risk. AbbVie may terminate on failure to pay within a specified cure period or on uncured material breach; comparable provisions exist in the Roche and Mabwell agreements. Loss of any licence would be catastrophic to the affected programme.
  • Burn is accelerating against a fixed clock. H1 2026 operating expenses of $134.6 million annualise to approximately $269 million. Advancing two additional programmes to pivotal stage in 2027, as management has signalled, would consume the runway cushion materially faster than the "into 2029" guidance implies.
  • Concentrated ownership and single-catalyst positioning create liquidity risk. With a beta of 2.05, average daily volume in the hundreds of thousands of shares, and disclosed 5%-plus holders controlling a large fraction of the register, the shares are structurally vulnerable to disorderly repricing around the Q4 readout.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr 2025APOLLO Phase 3 confirmatory trial of bitopertin in EPP initiatedTriggered a $10.0 million milestone to Roche; began the trial that now determines the entire bitopertin thesis
7 May 2025Q1 2025 results: net loss $34.1 million; cash $694.7 million; runway into 2028Modest loss quarter before the 2025 spending ramp
9 May 2025Virtual MF Anemia KOL Day hostedInvestor education ahead of first RALLY-MF data; signalled intent to build the oncology narrative
Jun 2025EHA 2025 presentations across the portfolioRoutine scientific dissemination
Jul 2025Nadim Ahmed appointed to the boardAddition of large-cap commercial haematology leadership
Jul 2025Board establishes a standing Commercial CommitteeInstitutionalises board-level launch oversight; met four times in the remainder of 2025
7 Aug 2025Q2 2025 results: net loss $55.2 million; EPS −$1.58 versus consensus −$1.17; cash $650.0 millionSignificant EPS miss driven by the $10.0 million Roche milestone and rising spend
Sep 2025NDA for bitopertin submitted to FDA under accelerated approval for patients 12 and older with EPP; Priority Review requestedThe pivotal regulatory event of 2025. Supported by BEACON and AURORA plus Roche's legacy safety database
10 Sep 2025Presentation at Morgan Stanley 23rd Annual Global Healthcare ConferenceInvestor engagement
Q3 2025First patient administered in the Phase 2 DISC-3405 study; $10.0 million milestone paid to MabwellAdvanced the hepcidin-induction franchise into patients
16 Oct 2025FDA grants Commissioner's National Priority Voucher for bitopertinCompressed the expected review to one to two months; a genuine differentiator and, at the time, a strong positive surprise
Oct 2025Underwritten offering of shares and pre-funded warrants; net proceeds $211.0 millionOpportunistic raise into CNPV-driven strength; extended runway into 2029
6 Nov 2025Q3 2025 results: net loss $62.3 million; R&D $50.3 millionPeak quarterly burn of the year
Q4 2025NDA accepted for Priority Review under the accelerated approval pathwayFormal start of the review clock
Q4 2025Phase 1b study of DISC-3405 in sickle cell disease initiatedSecond indication for DISC-3405
Q4 2025Composition-of-matter patent issued for DISC-0974 with exclusivity to 2041Materially strengthens the long-term economics of the selcodebart franchise
Dec 2025Initial Phase 2 RALLY-MF data presented at ASH: durable benefits on haemoglobin and transfusion burden across a broad patient range, efficacy independent of concomitant JAK inhibitor useEstablished selcodebart as a credible second value driver
12 Jan 20262026 business objectives released; unaudited year-end cash of $791 million confirmedGuidance still assumed a 2026 approval and launch
Jan 2026Blinded sample-size re-estimation performed on APOLLO; no adjustment requiredRemoved a source of trial-execution risk
Q1 2026Phase 2 study of DISC-0974 in anaemia of inflammatory bowel disease initiatedThird indication for selcodebart; initial data expected 2027
13 Feb 2026FDA issues Complete Response Letter for bitopertin in EPP. FDA accepted that AURORA and BEACON demonstrated significant reduction in whole-blood metal-free PPIX and acknowledged strong mechanistic and biological plausibility, but found no demonstrated association between percentage change in PPIX and sunlight-exposure-based endpoints as measured. FDA indicated it needs APOLLO results. CEO: *"The CRL will delay the potential approval of bitopertin, but we have confidence in the ongoing APOLLO trial"*The single most consequential event of the period. Invalidated the 2026 launch plan, deferred approval by roughly fifteen months, and demonstrated that CNPV status accelerates review timing but does not lower the evidentiary bar
26 Feb 2026FY2025 results and Form 10-K filed: net loss $212.2 million; R&D $170.6 million; SG&A $65.4 million; cash $791.2 million; runway into 2029Confirmed the balance sheet can absorb the delay without a raise
Mar 2026APOLLO completes enrolment ahead of schedule with a final N of 183Removed enrolment risk; locked the Q4 2026 readout date
Apr 2026AAD 2026: competitor Mitsubishi Tanabe reports positive Phase 3 INSPIRE results for oral dersimelagon in EPP/XLPMaterially raises the competitive stakes for a bitopertin launch
28 Apr 2026DEF 14A filed for the 18 June 2026 annual meetingDisclosed 145% 2025 bonus funding and 99.24% prior-year say-on-pay support
11–12 May 2026Investor conference participation announced; EHA 2026 abstract slate announced including RALLY-MF oral presentation, HELIOS update, EPP LIGHT survey and DISC-3405 dataPre-positioning for a data-heavy June
1 Jun 2026Expanded Access Programme launched for bitopertin in the US and select geographiesDelivers drug to patients during the regulatory gap and builds prescriber and patient relationships pre-launch
2 Jun 2026ASCO 2026: updated RALLY-MF data — durable overall anaemia responses across all subgroups regardless of baseline transfusion status or JAK inhibitor useBroadened the addressable MF anaemia population
9 Jun 2026Type A meeting outcome: FDA aligned that a successful APOLLO can serve as the basis for the CRL response and could potentially support traditional approvalStrategically superior to the original accelerated-approval path; removed post-marketing confirmatory obligations from the base case
12 Jun 2026EHA 2026: HELIOS open-label extension shows sustained PPIX reductions, significant improvement in light-tolerance measures and favourable longer-term safety; RALLY-MF data presentedThe light-tolerance improvement is the exact endpoint category the FDA said was unproven — supportive but not confirmatory
15 Jun 2026Study update conference call and slide deckReiterated Q4 APOLLO topline
18 Jun 20262026 annual meeting: Nicholson (28,559,799 votes), Quisel (33,433,078) and White (33,355,406) elected as Class III directors to 2029; say-on-pay approved 33,528,449 for versus 368,970 against with 9,830 abstentions and 2,011,469 broker non-votes; Ernst & Young ratifiedNote the roughly 4.9 million-vote gap between Nicholson and the other two nominees — the clearest signal of shareholder reservation in the period, likely reflecting proxy-adviser concern over the Executive Chairman's compensation-committee chairmanship or the 145% bonus outcome
Q2 2026EU Orphan Drug Designation granted for selcodebart in myelofibrosisFirst European regulatory step for the oncology franchise
30 Jul 2026Q2 2026 results: net loss $59.5 million; EPS −$1.54 versus consensus −$1.77 (beat); R&D $46.9 million; SG&A $18.1 million; cash $717.7 million; runway into 2029Spending discipline better than expected; the CEO flagged the potential to advance two more programmes into pivotal development in 2027
~18 Aug 2026Morgan Stanley raises price target to $90 from $85, maintaining Overweight (having earlier raised from $80 to $85 in June)Sell-side confidence rebuilding into the APOLLO readout
28 Aug 2026Competitor event: FDA approves rusfertide (Takeda / Protagonist Therapeutics) for polycythemia vera on the basis of the Phase 3 VERIFY trialThe PV market now has an approved hepcidin-pathway therapy before DISC-3405 has completed Phase 2
31 Aug 2026Multiple SOHO 2026 presentations announced across the portfolio—
2 Sep 2026Participation in upcoming investor conferences announced—
9–10 Sep 2026Initial RESTORE-PV Phase 2 results presented at SOHO: mean phlebotomy events fell from 4.0 to 0.6 per 26 weeks (p<0.0001); 61.5% phlebotomy-free through 26 weeks; 77.8% phlebotomy-free in the first maintenance period; haematocrit maintained below 45%; generally well tolerated. Described as the first anti-TMPRSS6 monoclonal antibody to demonstrate phlebotomy reduction in PVValidates the hepcidin-induction mechanism in patients and repositions Disc as a myeloproliferative neoplasm company. CEO frames the goal as *"durable disease control with straightforward, controllable, and convenient dosing"* — an explicit shot at rusfertide's weekly injection schedule
10–11 Sep 2026Presentations at Cantor Fitzgerald and Wells Fargo healthcare conferences; shares close at $70.06 on 11 September, down 5.50%Profit-taking after the SOHO run-up

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

1 chart
Results by Segment: Segment operating income fell from USD -30.9 Mn in FY2021 to USD -236 Mn in FY2025.
Disc Medicine Inc — Results by Segment
Series (USD Mn)FY2021FY2022FY2023FY2024FY2025
Segment operating income-30.9-47.5-91.1-129.7-236

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.